Kudzu Root Complex
Kudzu Root Complex, licence 80080306: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Ge Gen Complex
- Licence holder
- Nanjing Xiyuan Bio-Pharmaceutical Technology Co. Ltd.
- NPN or DIN-HM
- 80080306
- Status
- Active licence
- Licence date
- 28 September 2017
- Revision date
- 23 September 2026
- Form
- Capsule, molle
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Pueraria montana var. lobata (Willd.) Sanjappa & Pradeep: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Glycine max Source : Glycine max - Graine Potency : 25.0 Milligrammes d'équivalents aglycones d'isoflavones Isoflavones | 61.7 milligramme | Not calculated |
| Panax quinquefolius Source : Racine Extract : Matériel brut sec Extraction ratio : 6.0:1.0 Dry plant equivalent : 210.0 milligramme | 35.0 milligramme | Not calculated |
| Pueraria montana var. lobata Source : Racine Extract : Matériel brut sec Extraction ratio : 6.0:1.0 Dry plant equivalent : 330 milligramme | 55.0 milligramme | Not calculated |
| Lécithine Source : Glycine max - Graine | 35.0 milligramme | Not calculated |
Non-medicinal ingredients
Huile de pépin de raisin, Gélatine, Dioxyde de titane, Glycérine, Cire d'abeille, Eau purifiée
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 3.0 Capsule | 1.0 Tous les jours |
| Femmes en postménopause | Not specified | 3.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Used in Herbal Medicine as supportive therapy for the promotion of healthy glucose levels. American ginseng is traditionally used in Herbal Medicine to help relieve nervousness (as mild sedative). American ginseng is traditionally used in Herbal Medicine to help relieve nervous dyspepsia / to help digestion in cases of nervousness and/or stress. Used in Herbal Medicine as an adaptogen to help maintain a healthy immune system. Helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you currently have or previously had breast cancer and/or breast tumours or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or a family member with breast cancer.
- Précautions et mises en garde
Ensure you are up-to-date on mammograms and gynaecological evaluations prior to use. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use if you are taking blood thinners, or digoxin. Consult a health care practitioner prior to use if you have a history of hormonal or gynaecological disease, including ovarian cancer, endometriosis, and/or uterine fibroids. Consult a health care practitioner prior to use if you have a liver disorder or develop liver-related symptoms (e.g. abdominal pain, jaundice, dark urine). Consult a health care practitioner prior to use if you are taking hormone replacement therapy (HRT), including thyroid hormone replacement therapy. Discontinue use and consult a health care practitioner if you experience breast pain, discomfort and/or tenderness, or if you experience a recurrence of menstruation and/or uterine spotting. If you have diabetes, consult a health care practitioner prior to use.
Source
Official Health Canada record, licence 80080306
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.